[
    "{\"step_by_step_thinking\": \"Efgartigimod is indicated for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive as per Document [0]. This is further supported by Document [1] which states that Efgartigimod alfa was approved for medical use in the United States in December 2021. Document [2] also mentions that Efgartigimod is a promising biological drug for patients with moderate to severe generalized MG with or without anti-acetylcholine receptor antibodies in Japan. Therefore, Efgartigimod can be used for myasthenia gravis.\", \"answer_choice\": \"A\"}"
]